CS
RCUS icon

Credit Suisse’s Arcus Biosciences RCUS Stock Holding History

Credit Suisse’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$893K Hold
47,298
– – ﹤0.01% 2331
2023
Q4 		$903K Buy
47,298
+3,808
+9% +$60.9K ﹤0.01% 2399
2023
Q3 		$781K Sell
43,490
-12,658
-23% -$254K ﹤0.01% 2440
2023
Q2 		$1.14M Buy
56,148
+21,555
+62% +$410K ﹤0.01% 2294
2023
Q1 		$631K Sell
34,593
-2,886
-8% -$55.2K ﹤0.01% 2612
2022
Q4 		$775K Sell
37,479
-1,506
-4% -$41.4K ﹤0.01% 2519
2022
Q3 		$1.02M Buy
38,985
+9,552
+32% +$253K ﹤0.01% 2324
2022
Q2 		$746K Sell
29,433
-2,628
-8% -$64.4K ﹤0.01% 2580
2022
Q1 		$1.01M Sell
32,061
-1,723
-5% -$57.7K ﹤0.01% 2537
2021
Q4 		$1.37M Buy
33,784
+729
+2% +$28.3K ﹤0.01% 3077
2021
Q3 		$1.15M Buy
33,055
+2,487
+8% +$77.4K ﹤0.01% 3231
2021
Q2 		$834K Sell
30,568
-1,802
-6% -$51.5K ﹤0.01% 3523
2021
Q1 		$909K Sell
32,370
-32,187
-50% -$1.12M ﹤0.01% 3385
2020
Q4 		$1.68M Sell
64,557
-38,130
-37% -$923K ﹤0.01% 2953
2020
Q3 		$1.76M Buy
102,687
+36,493
+55% +$815K ﹤0.01% 2508
2020
Q2 		$1.64M Buy
66,194
+51,427
+348% +$1.39M ﹤0.01% 2547
2020
Q1 		$206K Buy
14,767
+3,345
+29% +$41.6K ﹤0.01% 3633
2019
Q4 		$115K Sell
11,422
-5,842
-34% -$49.1K ﹤0.01% 4057
2019
Q3 		$157K Buy
17,264
+1,877
+12% +$15.1K ﹤0.01% 3914
2019
Q2 		$122K Sell
15,387
-2,838
-16% -$28.4K ﹤0.01% 3932
2019
Q1 		$227K Buy
18,225
+4,996
+38% +$54.2K ﹤0.01% 3724
2018
Q4 		$143K Buy
+13,229
New +$154K ﹤0.01% 3727

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Credit Suisse's RCUS Position: Q1 2024 in Review

Credit Suisse held its Arcus Biosciences (RCUS) position steady in Q1 2024 at 47,298 shares worth $893K. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Credit Suisse first reported a position in RCUS in Q4 2018 and has held it in 22 quarters since. The position peaked at $1.76M in Q3 2020. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Credit Suisse held 47,298 shares of Arcus Biosciences worth $893K as of Q1 2024.
  • Credit Suisse left its Arcus Biosciences share count unchanged in Q1 2024.
  • Arcus Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2331 holding.
  • Credit Suisse first reported a position in Arcus Biosciences in Q4 2018 and has held it in 22 quarters since.
  • Credit Suisse's Arcus Biosciences position peaked at $1.76M in Q3 2020.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.